Sanofi Asks Judge to Decide Part of EpiPen Antitrust Suit Now

Sanofi-Aventis US LLC says a trial isn’t necessary to prove part of its claim that Mylan Inc. elbowed EpiPen’s competitors out of the market, then began price-gouging when its “stranglehold” was safe.

The drugmaker-on-drugmaker fight is part of a sprawling antitrust lawsuit, one of several consolidated cases filed against Mylan by competitors, consumers, and investors over steep increases in the cost of EpiPen. EpiPen is an epinephrine auto-injector, or EAI, that treats potentially fatal allergic reactions known as anaphylaxis.

Sanofi claims Mylan built a “$1 billion crown jewel enterprise” starting in 2007 when it acquired EpiPen’s rights, realized the lifesaving ...